ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

B2-Adrenergic Receptor Activation in Donor Cells Inhibits T Cell Trafficking in Vascularized Composite Tissue Allotransplants

M. Kim1, D. Fisher1, J. Loo1, P. Bogner2, U. Sharma3, J. Skitzki1, E. Repasky4

1Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 2Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 3Cardiology, University at Buffalo, Buffalo, NY, 4Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Meeting: 2020 American Transplant Congress

Abstract number: D-238

Keywords: Immunosuppression, Interferon (IFN), T cells

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session D: VCA

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Beta2-Adrenergic Receptor Activation Prolongs Survival of Vascularized Composite Tissue Allotransplants in a Murine Model
  • Donor HSCs from the Bone Component of Vascularized Composite Allografts Migrate to Recipient Thymus and Differentiate to Mature T Cells

*Purpose: Transplantation of faces, hands, and limbs using vascularized composite allotransplantation (VCA) has faced significant challenges hindering its routine implementation in the clinic. One critical hurdle is the scarcity of adequately matched HLA donors, requiring high doses of immunosuppressants which prevent rejection, but also present significant risks to the patient. New methods of controlling rejection are desperately needed. One possibility could be in exploiting the links between the nervous and immune systems that regulate host defense. The neurotransmitter norepinephrine acts through the β2-adrenergic receptors (β2-AR) to regulate immune cells resulting in immunosuppression. We hypothesize that β2-AR activation suppresses immune cell function after VCA.

*Methods: Heterotopic hind limb transplantation mouse model was used with C57BL/6 (H-2b) as recipients and BALB/c (H-2d) mice as donors. Graft survival was measured with and without treatment with the β2-agonist terbutaline, and the contribution to graft survival of β2-AR signaling in donor and recipient tissue was investigated.

*Results: Induced β2-AR signaling significantly inhibited CD4+/8+ T cell infiltration in the graft with delayed graft rejection without severe side effects (Figure; brown color with Rabbit horseradish peroxidase). The β2-AR agonist significantly decreased the proportion of CD4+/8+ central/effector memory T cell populations in allotransplanted mice. Additionally, a significant reduction was noted in IFNγ secreting CD4+ T cells as well as IFNγ and IL-6 levels in the terbutaline group compared to the vehicle group. Graft rejection was delayed when β2-AR was activated in either recipient or donor cells, however β2-AR signaling in donor cells was requited for inhibition of T cell infiltration into transplanted grafts.

*Conclusions: A selective β2-AR agonist, terbutaline, was safe and effective to delay immune activation and graft rejection after VCA. Encouragingly, β2-AR agonists could be used clinically to decrease doses of toxic immunosuppressive drugs used to maintain healthy grafts and may serve as a bridging therapy while recipients cannot take immunosuppressive drugs due to toxicities. Further investigation is needed to maximize the efficacy of β2-AR agonist in transplant immunosuppression.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kim M, Fisher D, Loo J, Bogner P, Sharma U, Skitzki J, Repasky E. B2-Adrenergic Receptor Activation in Donor Cells Inhibits T Cell Trafficking in Vascularized Composite Tissue Allotransplants [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/b2-adrenergic-receptor-activation-in-donor-cells-inhibits-t-cell-trafficking-in-vascularized-composite-tissue-allotransplants/. Accessed March 6, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Role of Mitochondria, Metabolism and Inflammation: Pathways Influencing Short Term Outcomes Post-Renal Transplantation
    • Factors Influencing Creatinine Rise Following Donor Nephrectomy

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.